公开(公告)号：US20240299514A1

公开(公告)日：2024-09-12

申请号：US18667742

申请日：2024-05-17

申请人： Diamyd Medical AB

发明人： Anders ESSEN-MÖLLER ,  Johnny LUDVIGSSON

IPC分类号： A61K39/00 ,  A61K9/00 ,  A61K31/192 ,  A61K31/197 ,  A61K31/592 ,  A61K31/593 ,  A61K35/12 ,  A61K38/17 ,  A61K38/19 ,  A61K38/28 ,  A61K38/43 ,  A61K45/06

CPC分类号： A61K39/0008 ,  A61K9/0019 ,  A61K31/192 ,  A61K31/197 ,  A61K31/592 ,  A61K31/593 ,  A61K38/1793 ,  A61K38/191 ,  A61K38/28 ,  A61K38/43 ,  A61K45/06 ,  C12Y401/01005 ,  A61K2035/122 ,  A61K2039/54 ,  A61K2039/55505 ,  A61K2039/577

摘要： The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject The subject may have a serum vitamin-D level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years. The invention also relates to a composition comprising a plurality of particles, each having immobilised on its surface at least one first and at least one second antigen, wherein the first antigen is a beta cell autoantigen, and the second antigen is either a tolerogen or a beta cell autoantigen, and to composition comprising i) at least one beta cell autoantigen, and at least one of iia) an IL-10 inducing compound selected from the group consisting of vitamin-D), vitamin-D analogs, tyrosine kinase inhibitors, gamma-amino butyric acid, and gamma-amino butyric acid analogs; and iib) a compound that reduces the dendritic cells' ability to activate naïve CD4+ Tcells, such as a cyclooxygenase inhibitor, a CTLA-4 compound or a TNF alpha inhibitor. The invention also relates to pharmaceutical kits and to medical use of beta cell autoantigens.

公开(公告)号：US12071478B2

公开(公告)日：2024-08-27

申请号：US16331171

申请日：2017-09-07

申请人： Daiichi Sankyo Company, Limited

发明人： Ryuta Mukasa ,  Kensuke Nakamura ,  Sumie Muramatsu ,  Naoyuki Makita

IPC分类号： A61P21/00 ,  A61K31/56 ,  A61K39/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/16 ,  A61P7/04 ,  A61P7/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K16/28 ,  C07K16/46 ,  C12N5/10 ,  C12N15/09 ,  A61K35/12

CPC分类号： C07K16/2803 ,  A61K31/56 ,  A61K39/0008 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/16 ,  A61P7/04 ,  A61P7/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K16/28 ,  C07K16/46 ,  C12N5/10 ,  C12N15/09 ,  A61K2035/122 ,  A61K2039/505 ,  A61K2039/577 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

摘要： Provided are methods for treatment or prevention of an autoimmune disease that comprise administering a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.

公开(公告)号：US20240269269A1

公开(公告)日：2024-08-15

申请号：US18494491

申请日：2023-10-25

申请人： Barinthus Biotherapeutics North America, Inc. ,  The United States of America, as represented by the Secretary, Department of Health

发明人： Geoffrey Martin Lynn ,  Christopher Martin O’Brien Garliss ,  Andrew Scott Ishizuka ,  Hugh Clarke Welles

IPC分类号： A61K39/385 ,  A61K39/00 ,  A61K39/35 ,  A61K47/54 ,  A61K47/64 ,  A61K47/69 ,  A61P3/10 ,  A61P37/06

CPC分类号： A61K39/385 ,  A61K39/35 ,  A61K47/545 ,  A61K47/549 ,  A61K47/646 ,  A61K47/6935 ,  A61P3/10 ,  A61P37/06 ,  A61K2039/54 ,  A61K2039/577 ,  A61K2039/6093

摘要： The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]—H and H—[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

公开(公告)号：US12048765B2

公开(公告)日：2024-07-30

申请号：US15111466

申请日：2015-01-16

申请人： FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL ,  FUNDACIÓ INSTITUT CATALÀ DE NANOCIÊNCIA I NANOTECNOLOGIA ,  INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANATS

发明人： Daniel Maspoch Comamala ,  Antonia Maria Cano Sarabia ,  Marta Vives Pi ,  Irma Pujol Autonell ,  Juan Verdaguer Autonell

IPC分类号： A61K39/00 ,  A61K9/127

CPC分类号： A61K9/127 ,  A61K39/0008 ,  A61K2039/577

摘要： The present invention provides a liposome encapsulating an autoantigen, wherein the liposome has a size comprised from 500 to 15000 nm and the liposome membrane comprises phosphatydilserine (PS) in an amount comprised from 10 to 40% by weight with respect to the total membrane liposomal composition. Pharmaceutical or veterinary compositions comprising a therapeutically effective amount of said liposome are also provided. Further, the invention provides liposomes and pharmaceutical or veterinary compositions as defined above for use as a medicament, particularly for the treatment of autoimmune diseases. Finally the present invention provides liposomes and pharmaceutical or veterinary compositions as defined above for use in the restoration of tolerance to self in a patient suffering from an autoimmune disease.

公开(公告)号：US12016917B2

公开(公告)日：2024-06-25

申请号：US16842675

申请日：2020-04-07

申请人： SOCIETE DES PRODUITS NESTLE S.A.

发明人： Bryan Walser ,  Howard V. Raff

IPC分类号： A61K39/35 ,  A23L25/00 ,  A23L33/185 ,  A61K39/00 ,  G01N33/483 ,  G01N33/68

CPC分类号： A61K39/35 ,  A23L25/30 ,  A23L33/185 ,  G01N33/483 ,  G01N33/6893 ,  A23V2002/00 ,  A61K2039/542 ,  A61K2039/577 ,  G01N2500/20 ,  G01N2800/24

摘要： The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy.

公开(公告)号：US20230346900A1

公开(公告)日：2023-11-02

申请号：US18218943

申请日：2023-07-06

申请人： Cue Biopharma, Inc.

发明人： Ronald D. Seidel, III ,  Rodolfo J. Chaparro ,  John F. Ross ,  Chee Meng Low

IPC分类号： A61K39/00 ,  C07K14/74 ,  C07K14/705 ,  C07K14/62 ,  C12N9/88 ,  A61P3/10 ,  A61P37/06

CPC分类号： A61K39/0008 ,  C07K14/70539 ,  C07K14/70532 ,  C07K14/62 ,  C12N9/88 ,  A61P3/10 ,  A61P37/06 ,  C07K2319/30 ,  A61K2039/577 ,  A61K2039/645 ,  A61K2039/605

摘要： The present disclosure provides T-cell modulatory multimeric polypeptides (TMMPs) comprising a type 1 diabetes (T1D)-associated peptide epitope, MHC class II polypeptides, and one or more immunomodulatory polypeptides. A TMMP of the present disclosure is useful for modulating activity of a T cell. Thus, the present disclosure provides compositions and methods for modulating the activity of T cells, as well as compositions and methods for treating persons who have T1D.

公开(公告)号：US20230310593A1

公开(公告)日：2023-10-05

申请号：US18064211

申请日：2022-12-09

申请人： Selecta Biosciences, Inc.

发明人： Takashi Kei Kishimoto ,  Christopher Fraser ,  Roberto A. Maldonado

IPC分类号： A61K39/385 ,  A61K39/35 ,  G01N33/50 ,  G01N33/569 ,  A61K39/00 ,  A61K9/127 ,  A61K9/51 ,  A61K38/38 ,  A61K47/50 ,  A61K47/52 ,  A61K47/54 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  B82Y5/00 ,  A61K39/36 ,  A61K31/192 ,  A61K9/14 ,  A61K38/13 ,  A61K38/18

CPC分类号： A61K39/385 ,  A61K39/35 ,  G01N33/505 ,  G01N33/56972 ,  A61K39/001 ,  A61K39/0008 ,  A61K9/127 ,  A61K9/5146 ,  A61K38/38 ,  A61K47/50 ,  A61K47/52 ,  A61K47/544 ,  A61K47/593 ,  A61K47/643 ,  A61K47/69 ,  A61K47/6923 ,  A61K47/6929 ,  A61K47/6937 ,  A61K39/00 ,  B82Y5/00 ,  A61K39/36 ,  A61K9/5115 ,  A61K31/192 ,  A61K9/14 ,  A61K38/13 ,  A61K9/5153 ,  A61K38/1816 ,  A61K9/51 ,  G01N2333/70517 ,  G01N2333/70514 ,  G01N2333/7051 ,  A61K2039/5154 ,  A61K2039/577 ,  A61K2039/55511 ,  A61K2039/55555 ,  Y02A50/30 ,  B82Y40/00

摘要： Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.

公开(公告)号：US20230302105A1

公开(公告)日：2023-09-28

申请号：US17931868

申请日：2022-09-13

申请人： CREATIVE MEDICAL TECHNOLOGIES INC.

发明人： Thomas Ichim ,  Amit Patel

IPC分类号： A61K39/00 ,  A61K35/28 ,  C12N5/0775

CPC分类号： A61K39/0008 ,  A61K35/28 ,  C12N5/0665 ,  A61K2039/577 ,  C12N2502/137 ,  A61K2039/5158

摘要： Described are antigen specific and antigen non-specific means of suppressing development of Type 1 Diabetes in a mammal through administration of exosomes, microvesicles or apoptotic bodies from monocytic lineage cells that have been reprogrammed by contact with mesenchymal stem cells and/or mesenchymal stem cell conditioned media. In one embodiment, the invention provides administration of exosomes that have been generated from monocytic cells that have been loaded with tolerogenic antigens and/or epitopes. In another embodiment the invention provides administration of allogeneic myeloid derived exosomes that are loaded with tolerogenic antigens. In another embodiment the invention provides means of stimulating exosome release in vivo from allogeneic cells that have been administered to the patient in need of treatment.

公开(公告)号：US20180187152A1

公开(公告)日：2018-07-05

申请号：US15905176

申请日：2018-02-26

申请人： Baylor College of Medicine

发明人： Ann Marie Leen ,  Juan Fernando Vera Valdes ,  Cliona M. Rooney ,  Ulrike Gerdemann

IPC分类号： C12N5/0783 ,  C12N7/00 ,  A61K39/12 ,  A61K39/00

CPC分类号： C12N5/0638 ,  A61K39/12 ,  A61K2039/5158 ,  A61K2039/55527 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/577 ,  A61K2039/70 ,  C12N7/00 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2710/16134 ,  C12N2710/16234 ,  Y02A50/394 ,  Y02A50/467

摘要： The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.

公开(公告)号：US09993548B2

公开(公告)日：2018-06-12

申请号：US14161660

申请日：2014-01-22

申请人： Selecta Biosciences, Inc.

发明人： Roberto A. Maldonado

IPC分类号： A61K47/48 ,  A61K39/00 ,  C07K16/18 ,  A61K9/51 ,  A61K9/58 ,  A61K47/00 ,  A61K9/14 ,  A61K39/385 ,  A61K39/35 ,  G01N33/50 ,  G01N33/569 ,  B82Y5/00 ,  A61K39/36 ,  A61K9/127 ,  A61K38/38 ,  A61K31/192 ,  A61K38/13 ,  A61K38/18 ,  A61K47/50 ,  A61K47/52 ,  A61K47/54 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  B82Y40/00

CPC分类号： A61K39/385 ,  A61K9/127 ,  A61K9/14 ,  A61K9/51 ,  A61K9/5115 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/192 ,  A61K38/13 ,  A61K38/1816 ,  A61K38/38 ,  A61K39/00 ,  A61K39/0008 ,  A61K39/001 ,  A61K39/35 ,  A61K39/36 ,  A61K47/50 ,  A61K47/52 ,  A61K47/544 ,  A61K47/593 ,  A61K47/643 ,  A61K47/69 ,  A61K47/6923 ,  A61K47/6929 ,  A61K47/6937 ,  A61K2039/5154 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/577 ,  B82Y5/00 ,  B82Y40/00 ,  G01N33/505 ,  G01N33/56972 ,  G01N2333/7051 ,  G01N2333/70514 ,  G01N2333/70517 ,  Y02A50/401 ,  Y02A50/41 ,  A61K2300/00

摘要： Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells.